galeratx.com - הכנסה לפני ניכוי ריבית, מסים ופחת GRTX

Is it worth investing in Galera Therapeutics (GRTX), whose radiation-induced stomatitis treatments rely on grants and investments? The EBITDA financial metric provides the answer, and the value of captures this indicator. Risks are increasing due to the complete outsourcing of testing and drug production to third-party contractors. Meanwhile, Galera Therapeutics is implementing software robots for data analysis and automating laboratory molecule screening.

To stress-test long-term positions, it is critical for an investor to evaluate the actual cash flow from core operations before taxes and depreciation. Analyzing the level of net operating income before depreciation allows Galera Therapeutics (GRTX) to confirm the monetization of its radiation tissue protection drugs, transforming steady hospital demand into actual liquidity, which determines the fundamental stability of the business.